Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07807033
Starting soon Observational

Observation of Immune Persistence in a Clinical Trial of an Adsorbed Tetanus Vaccine

NCT07807033 · tracked via the Priya Life Science China tracker
Sponsor
CanSino Biologics Inc
Phase
Observational
Started
2026-10-15
Last updated
2026-09-08

Condition(s) studied

Tetanus

Investigational drug(s) / intervention(s)

Previously vaccinated with TTVAPreviously vaccinated with TT

Previously vaccinated with TTVA: 3.0 to 4.0 mL of venous blood will be collected for the immunodynamic study.

Previously vaccinated with TT: 3.0 to 4.0 mL of venous blood will be collected for the immunodynamic study.

Study summary

This study included 240 trial participants who had previously taken part in a Phase III clinical trial of an adsorbed tetanus vaccine (Protocol No.: CTP-TTVA-001), with 120 participants in each of the treatment and control groups. All trial participants were required to provide 3.0-4.0 mL of blood for an immunodurability assessment 2.5 years after vaccination.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Individuals who have previously participated in the Phase III clinical trial of the adsorbed tetanus vaccine (Protocol No.: CTP-TTVA-001). * Willing to provide identification documents. * Have given informed consent, voluntarily signed the informed consent form, and are able to comply with the requirements of the clinical trial protocol. * At least 2.5 years have elapsed since completion of the vaccination series. Exclusion Criteria: * Following vaccination in the Phase III clinical trial (Protocol No.: CTP-TTVA-001), participants who have received tetanus immunoglobulin, tetanus antitoxin, or a vaccine containing tetanus toxoid antigen. * Participants in the previous Phase III clinical trial (Protocol No.: CTP-TTVA-001) who did not complete the blood draw 30 days after vaccination. * Other circumstances deemed by the investigator to render a participant ineligible for this clinical study.

Primary outcome measure(s)

  • Positivity rate of IgG antibodies against tetanus toxoid. — 2.5 years after vaccination
  • Geometric mean concentration (GMC) against tetanus toxoid. — 2.5 years after vaccination
  • The proportion of antibody concentrations ≥ 1.0 IU/mL 2.5 years after vaccination. — 2.5 years after vaccination

Trial sites (1)

FacilityCityRegionStatus
Center for Disease Control and Prevention, Qixingguan District, Bijie City Bijie Guizhou

More CanSino Biologics Inc. trials in China

Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine Active, not recruiting
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds Active, not recruiting
Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine Active, not recruiting
Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine Recruiting
A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP) Active, not recruiting

Other trials for the same condition

A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents) Recruiting
Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine Starting soon
A Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury Recruiting
A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury Recruiting
A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07807033 on ClinicalTrials.gov ↗ ← All trials in China